Antisense oligonucleotides to p53

• US 5,654,415 A
• Filed: 10/21/1994
• Issued: 08/05/1997
• Est. Priority Date: 08/23/1991
• Status: Expired due to Term

• Current Assignee: Board of Regents of the University of Nebraska
• Original Assignee: Board of Regents of the University of Nebraska
• Inventors: Smith, Larry James
• Primary Examiner(s): Chambers, Jasemine C.
• Assistant Examiner(s): Crouch, Deborah
• Application Number:
  US08/327,371
• Time in Patent Office: 1,019 Days
• Field of Search: 536/24.5, 514/44, 935/34, 935/36
• US Class Current: 536/24.5
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 15/1135 against oncogenes or tumor suppressor genes
• CPC Class Codes: C12N 2310/13 Decoys
• CPC Class Codes: C12N 2310/315 Phosphorothioates

Abstract

Antisense oligonucleotides and composition of oligonucleotides are taught which inhibit the proliferation of cells without affecting cell viability. p53 antisense oligonucleotides are shown to inhibit the proliferation of tissue culture cells expressing this gene. Methods of treating a patient with such antisense oligonucleotides is described.

Claims

1. An oligonucleotide, selected from the group consisting of:

5'"'"'-ATCTGACTGC GGCTCCTCCA-3'"'"' (Sequence I.D. No.

     2)

5'"'"'-GACAGCATCA AATCATCCAT-3'"'"' (Sequence I.D. No.

     3)

5'"'"'-CCCTGCTCCC CCCTGGCTCC-3'"'"' (Sequence I.D. No.

     4)

5'"'"'-AGTCTTGAGC ACATGGGAGG-3'"'"' (Sequence I.D. No.

     5).

2. The oligodeotide of claim 1 wherein the melting point is equal to or greater than 40°

C.

3. A modified oligonucleotide as claimed in claim 1, having a modification selected from the group consisting of phosphorothioate modification, dithioate modification, methylphosphonate modification and ethylphosphonate modification.